Is there a generic version of Xadago (safinamide)?
As of the latest publicly available patent-tracking information, DrugPatentWatch does not list a released generic for Xadago (safinamide) under the brand name Xadago. [1]
When would a Xadago generic be expected to launch (patent/exclusivity timing)?
Generic entry timing usually depends on when relevant patents and any regulatory exclusivity end for safinamide (Xadago). For the most direct, up-to-date check on those dates and which patents matter, DrugPatentWatch is the most relevant starting point because it tracks patent status and challenges. [1]
What drug is Xadago, and what would a generic have to match?
Xadago’s active ingredient is safinamide. A true “generic Xadago” would be required to have the same active ingredient (safinamide) and demonstrate bioequivalence to the reference product (per FDA generic-approval standards). Patent status determines whether FDA can approve a generic for marketing; it does not change the requirement that the generic match the reference drug. [1]
If no generic exists yet, what are common alternatives?
If you’re looking for a safinamide alternative specifically, the practical options today are usually:
- staying on brand Xadago, or
- discussing other Parkinson’s disease treatments with a clinician if cost or availability is the driver.
Patent status can affect generic availability, but it doesn’t provide substitutes for safinamide’s specific place in treatment; that decision depends on your diagnosis, current meds, and tolerability.
How to check the latest “generic Xadago” status yourself
Search DrugPatentWatch for “Xadago” to see:
- which patents are listed for safinamide,
- whether there are any ANDA-related challenges,
- and the tracked timeline toward potential generic entry. [1]
Sources:
[1] https://drugpatentwatch.com/